asa glp-1 agonist guidelines 🔸 Should RAs be continued preprocedurally? 🔸 Who should stop a GLP-1 RA preoperatively? 🔸 Which patients should have their procedures postponed? Read: https://doi.org/10.1097/01.ASM.0001125664.22893.9f 2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations

Moreover, the combination of glucagon with GLP-1 actions could improve WL while protecting against the risk of hyperglycaemia [64]

1 Given the differences within the drug class, switching from one GLP1RA to another may be beneficial and may delay the need to intensify therapy, thus avoiding an increase in treatment burden

There is no evidence that supplementing will restart a weight plateau, but you made need some none the less

Abstract Introduction Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective for glycaemic control and weight loss in patients with type 2 diabetes (T2D)

Sherrill CH, Hwang AY

In France, the semaglutide 2.4-mg (Wegovy) was part of an early-access initiative from July 2022 to September 2023